Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: A clinical and neurophysiological study

References

• Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, . Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2000; 69:121–3.
   PubMed Web of Science ®Google Scholar
• Cummings CW, Frederickson JM, Harker LA, Krause CK, Schuller DE, Richardson MA. Otolaryngology head and neck surgery, physiology. 3rd St. Louis: Mosby-Year Book Inc.; 1998. 1219.
   Google Scholar
• Baltadzhieva R, Gurevich , Korczyn AD. Autonomic impairment in amyotrophic lateral sclerosis. Curr Opin Neurol. 2005; 18:487–3.
   PubMed Web of Science ®Google Scholar
• Johnson H, Scott A. Saliva management. Cichero J, Murdoch B. Dysphagia, Foundations, Theory and Practice; Wiley & Sons Ltd, Chichester 2006. 126–45.
   Google Scholar
• Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, . EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. An evidence based review with good practice points. Eur J Neurol. 2005; 12:921–38.
   PubMed Web of Science ®Google Scholar
• Lew KM, Younis RT, Lazar RH. The current management of sialorrhoea. Ear Nose Throat J. 1991; 70:99–105.
   PubMedGoogle Scholar
• Naumann M, Jost WH, Toyka KV. Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch Neurol. 1999; 56:914–6.
   PubMedGoogle Scholar
• Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, de Camilli P, . Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993; 365:160–3.
   PubMed Web of Science ®Google Scholar
• Naumann M, Flachenecker P, Bröcker EB, Toyka KV, Reiners K. Botulinum toxin for palmar hyperhydrosis. Lancet. 1997; 349:252–3.
   PubMedGoogle Scholar
• Bushara KO. Sialorrhoea in amyotrophic lateral sclerosis: a hypothesis of a new treatment – botulinum toxin A injections of the parotid glands. Med Hypotheses. 1997; 48:337–9.
   PubMed Web of Science ®Google Scholar
• Meningaud JP, Pitak-Arnnop P, Chikhani L, Bertrand JC. Drooling of saliva: a review of the aetiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 101:48–57.
   PubMed Web of Science ®Google Scholar
• Bhatia KP, Munchau A, Brown P. Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry. 1999; 67:697.
   PubMed Web of Science ®Google Scholar
• Porta M, Gamba M, Bertacchi G, Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry. 2001; 70:538–40.
   PubMed Web of Science ®Google Scholar
• Winterholler MG, Erbguth FJ, Wolf S, Kat S. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side-effects of a transductal approach. J Neurol Neurosurg Psychiatry. 2001; 70:417–8.
   PubMed Web of Science ®Google Scholar
• Tan EK, Lo YL, Seah A, Auchus AP. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci. 2001; 190:95–7.
   PubMed Web of Science ®Google Scholar
• Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003; 61:1279–81.
   PubMed Web of Science ®Google Scholar
• Meijer JW, van Kuijk AA, Geurts AC, Schelhaas HJ, Zwarts MJ. Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2008; 87:321–4.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 1(5):293–9.
   PubMed Web of Science ®Google Scholar
• ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol. 1996; 53:141–7.
   PubMedGoogle Scholar
• White KS, Sher KJ. Saliva: a review and experimental investigation of major techniques. Psychophysiology. 1977; 14:203–12.
   PubMedGoogle Scholar
• Montecucco C, Schiavo G. Tetanus and botulism neurotoxins: a new group of zinc proteases. Trend Bio Sci. 1993; 18:324–7.
   PubMed Web of Science ®Google Scholar
• Verma A, Steele J. Botulinum toxin improves sialorrhoea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve. 2006; 34:235–7.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhoea in Parkinson's disease. Neurology. 2004; 62:37–40.
   PubMed Web of Science ®Google Scholar
• Costa J, Rocha ML, Ferreira J, Evangelista T, Coelho M, de Carvalho M. Botulinum toxin type B improves sialorrhoea and quality of life in bulbar onset amyotrophic lateral sclerosis. J Neurol. 2008; 255:545–50.
   PubMed Web of Science ®Google Scholar
• Charchaflie RJ, Bustos Fernandez L, Perec CJ, Gonzalez E, Marzi A. Functional studies of the parotid and pancreas glands in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1974; 37:863–7.
   PubMed Web of Science ®Google Scholar
• Schneyer LH. Method for the collection of separate submaxillary and sublingual saliva in man. J Dent Res. 1955; 34:257–61.
   PubMedGoogle Scholar
• Enfors BO. The parotid and submandibular secretion in man. Quantitative recordings of the normal and pathological activity. Acta Otolaryngol Suppl. 1962; 172:1–67.
   PubMedGoogle Scholar
• Manrique D. Application of botulinum toxin to reduce saliva in patients with amyotrophic lateral sclerosis. Braz J Otorhinolaryngol. 2005; 71:566–9.
   PubMedGoogle Scholar
• Contarino MF, Pompili M, Tittoto P, Vanacore N, Sabatelli M, Cedrone A, . Botulinum toxin B ultrasound-guided injections for sialorrhoea in amyotrophic lateral sclerosis and Parkinson's disease. Parkinsonism Relat Disord. 2007; 13:299–303.
   PubMedGoogle Scholar
• Suskind DL, Tilton A. Clinical study of botulinum A toxin in the treatment of sialorrhoea in children with cerebral palsy. Laryngoscope. 2002; 112:73–81.
   PubMed Web of Science ®Google Scholar
• Ellies M, Gottstein U, Rohrbach-Volland S, Arglebe C, Laskawi R. Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis. Laryngoscope. 2004; 114:1856–60.
   PubMedGoogle Scholar
• Nóbrega AC, Rodrigues B, Torres AC, Enzo A, Melo A. Does botulinum toxin decrease frequency and severity of sialorrhoea in Parkinson's disease?. J Neurol Sci. 2007; 253:85–7.
   PubMedGoogle Scholar
• Lange DJ, Rubin M, Greene PE, Kang UJ, Moskowitz CB, Brin MF, . Distant effects of locally injected botulinum toxin: a double-blind study of single fibre EMG changes. Muscle Nerve. 1991; 14:672–5.
   PubMed Web of Science ®Google Scholar
• Garner CG, Straube A, Witt TN, Gasser T, Oertel WH. Time-course of distant effects of local injections of botulinum toxin. Mov Disord. 1993; 8:33–7.
   PubMed Web of Science ®Google Scholar
• Eleopra R, Tugnoli V, Caniatti L, Gasser T, de Grandis D. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology. 1996; 46:1158–60.
   PubMed Web of Science ®Google Scholar
• Lorenzano C, Bagnato S, Gilio F, Fabbrini G, Berardelli A. No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm. Neurotox Res. 2006; 9:141–4.
   PubMed Web of Science ®Google Scholar